FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Friday

 

FDA Accepts New Drug Application for Osmotica Pharmaceutical’s Ontinua ER for Spasticity in MS

Osmotica Pharmaceutical Corp. recently announced that the FDA accepted its New Drug Application (NDA) for OntinuaTM ER. The application covers OntinuaTM ER () extended-release tablets for  of spasticity in patients with multiple sclerosis(MS).

MS is an inflammatory disease of the central nervous system. In the US, 400,00 people suffer from the disease and, worldwide, MS affects more than 2.3 million individuals. Fifty percent of MS patients suffer from spasticity, which involves feelings of stiffness and muscle spasms. Spasticity can be mild or severe, causing painful and uncontrollable extremities spasms. To prevent the deterioration of knees, shoulders, ankles, elbows and hips, appropriate treatment is necessary.

OntinuaTM ER given twice a day was shown to meet the co-primary endpoints of the Modified Ashworth Scale and the Clinical Global Impression of Change in the clinical study,” said Mark Stacy, MD, Vice Dean for Clinical Research, Duke University School of Medicine and head of the Osmotica’s Scientific Advisory Board. “OntinuaTM ER represents a great treatment option for MS patients with spasticity, and we look forward to bringing this therapy to patients.”

Using our proprietary OsmodexTM technology, we have developed OntinuaTM ER, a tablet that is intended to treat spasticity in patients with Multiple Sclerosis,” said Praveen Tyle, , President and CEO of Osmotica Pharmaceutical Corp. “We believe this product represents an innovative option for clinicians and physicians and we look forward to bringing this therapy to our patients upon regulatory approval.”

OsmolexTM ER is a once/daily drug formulation of Amantadine HCI Extended Release Tablets which uses the company’s OsmodexTM  and represents a new strategy to treat patients with Parkinson’s disease who have  dyskinesia (“LID”). In July, OsmolexTM ER was granted orphan exclusivity.

Osmotica’s clinical program for OsmolexTM ER comprises two phase 3 clinical trials assessing two doses (240 mg and 320 mg) in a population of 324 patients. In 2016, the company intends to file a 505 (b) (2) New Drug Application for OsmolexTM ER for patients with Parkinson’s disease. The company developed its OsmodexTM platform in the 1980’s and its products, which are used worldwide, have aggregated sales of over $2.0 billion.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length
Click here to read original article

Labels:



Go to Newer News Go to Older News